News Focus
News Focus
icon url

Scottwny

07/18/17 5:06 PM

#190839 RE: sox040713 #190834

I have been referring to another report that shows 33%. Here are the two reports though:

33%: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206088Orig1s000StatR.pdf

40%:
http://ir.celgene.com/releasedetail.cfm?releaseid=902701

I don't have time to look into the differences between the trials, but it's interesting that IPIX posted Otezla's graph of 33% on their Corporate Overview (which is what I thought we were aiming to beat). I'll look into it later tonight.
icon url

stevo99

07/18/17 5:54 PM

#190846 RE: sox040713 #190834

IIRC Otezla only had around 13% PASI 75 at 6 weeks so that's the first hurdle with the soon to be released interim P